All In MedTech

Device Trial Radar · NCT07393880

Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus

Non-Invasively Re-Training the Tinnitus Brain Using Bimodal Electrical-Sound Stimulation (NITESGON-ADT): Protocol for a Prospective, Double-Blind, Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Sep 30, 2028

Study completion Jan 30, 2029

Sponsor

Lead sponsor
University of Dublin, Trinity CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 6, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Factorial
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study tests whether pairing non-invasive stimulation of the greater occipital nerve (NITESGON) with an attentionally demanding auditory frequency discrimination training task reduces tinnitus loudness and tinnitus-related distress. One hundred adults with chronic tonal tinnitus will be randomised to one of four groups in a 2×2 factorial design: real versus sham NITESGON and active versus passive listening during auditory stimulation. Participants complete eight sessions across four weeks, with outcomes assessed at baseline, end of treatment, 28 days post-treatment, and 6 months post-treatment.

Conditions

  • Tinnitus, Subjective
  • Tinnitus
  • Chronic Tinnitus

Interventions

  • Real NITESGONDevice

    Real NITESGON is delivered transcutaneously via two saline-soaked sponge electrodes (35 cm² each) positioned bilaterally over the C2 dermatomes to target the greater occipital nerve. Stimulation consists of a constant direct current of 1.5 mA (tDCS), ramped up over 30 seconds and ramped down over 5 seconds. It is administered concurrently with the task for approximately 45 minutes per session, across eight sessions (2/week) over 4 weeks.

  • Sham NITESGONDevice

    Sham NITESGON is delivered using two saline-soaked sponge electrodes (35 cm² each) positioned bilaterally over the C2 dermatomes. The sham condition mimics real stimulation sensations via a 30-second ramp-up followed by a brief ramp-down, with no sustained current thereafter. Sham is administered concurrently with the task for \~45 minutes per session, across eight sessions (2/week) over 4 weeks.

  • Active ListeningBehavioral

    ADT is delivered using a three-interval, three-alternative forced-choice (3I-3AFC) frequency discrimination task. Standard tone frequencies are individually selected using equivalent rectangular bandwidth (ERB) spacing, centred on each participant's dominant tinnitus pitch, with five frequencies positioned at -5, -3, -1, +1, and +3 ERB relative to the tinnitus pitch. Frequencies are restricted to the range of 250-13,000 Hz. Tones are presented binaurally via headphones, with presentation levels individually calibrated using audiometric thresholds and frequency-specific reference equivalent threshold sound pressure levels (RETSPLs), subject to the protocol's sound pressure level limits.

  • Passive Listening (Control)Behavioral

    VisDT uses a three-interval, three-alternative forced-choice (3I-3AFC) paradigm with Gabor patches (sinusoidal gratings windowed by a Gaussian envelope) of fixed spatial frequency (6 cycles/degree) and fixed spatial spread. On each trial, one interval contains an orientation deviant relative to the standard. During VisDT, participants attend to the visual task while concurrent binaural tones are presented passively using a predetermined, non-adaptive schedule. Auditory frequencies are individually selected using equivalent rectangular bandwidth (ERB) spacing, centred on each participant's dominant tinnitus pitch, with five frequencies positioned at -5, -3, -1, +1, and +3 ERB relative to the tinnitus pitch. Frequencies are restricted to 250-13,000 Hz, and presentation levels are individually calibrated using audiometric thresholds and frequency-specific reference equivalent threshold sound pressure levels (RETSPLs), subject to the protocol's sound pressure level limits.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tinnitus Loudness (Visual Analogue Scale, VAS 0-100)Time frame: Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
  2. Tinnitus Functional Index (TFI, 0-100)Time frame: Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.
  3. Tinnitus Handicap Inventory (THI, 0-100)Time frame: Baseline visit, end of treatment at 4 weeks, 28 days post-treatment, and 6 months post-treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Trinity College Institute of Neuroscience (TCIN)

    Dublin, Dublin, Ireland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.